IV Baxdela delafloxacin: Phase III data

Top-line data from the double-blind, international Phase III RX-3341-303 trial in 850 patients with ABSSSIs showed that IV-to-oral Baxdela met the FDA-defined primary endpoint of non-inferiority to standard of care (SOC)

Read the full 310 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE